FLUCELVAX QUADRIVALENTの薬剤に関する洞察と市場予測：2032年

FLUCELVAX QUADRIVALENT（インフルエンザワクチン）は、連続細胞株であるMDCK（Madin Darby Canine Kidney）細胞で増殖させた細胞由来候補ワクチンウイルス（CVV）を用いて製造されたサブユニットインフルエンザワクチンです。これらの細胞は、培養液中で懸濁状態で自由に増殖するように適合されています。ウイルスはB-プロピオラクトンで不活化され、洗浄剤の臭化セチルトリメチルアンモニウムで破壊され、いくつかの工程を経て精製されます。4種類のウイルス株はそれぞれ製造され、別々に精製された後、4価ワクチンを製造するためにプールされます。

2019年、同社は欧州委員会が新しい細胞ベースの季節性インフルエンザワクチンであるFLUCELVAX TETRAインフルエンザの販売承認を発行したと発表しました。

今後数年間で、季節性インフルエンザの市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、FLUCELVAX QUADRIVALENTの優位性に影響を与える可能性のある機会を模索しています。季節性インフルエンザに対する他の新興製品は、FLUCELVAX QUADRIVALENTに厳しい市場競合を与えることが予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要6ヶ国におけるFLUCELVAX QUADRIVALENT市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 季節性インフルエンザに対するFLUCELVAX QUADRIVALENTの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 FLUCELVAX QUADRIVALENT市場評価

• 季節性インフルエンザに対するFLUCELVAX QUADRIVALENTの市場展望
• 主要6ヶ国市場分析
  • 主要6ヶ国における季節性インフルエンザに対するFLUCELVAX QUADRIVALENTの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: FLUCELVAX QUADRIVALENT, Clinical Trial Description, 2023
• Table 2: FLUCELVAX QUADRIVALENT, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: FLUCELVAX QUADRIVALENT Market Size in the 6MM, in USD million (2019-2032)
• Table 6: FLUCELVAX QUADRIVALENT Market Size in the US, in USD million (2019-2032)
• Table 7: FLUCELVAX QUADRIVALENT Market Size in Germany, in USD million (2019-2032)
• Table 8: FLUCELVAX QUADRIVALENT Market Size in France, in USD million (2019-2032)
• Table 9: FLUCELVAX QUADRIVALENT Market Size in Italy, in USD million (2019-2032)
• Table 10: FLUCELVAX QUADRIVALENT Market Size in Spain, in USD million (2019-2032)
• Table 11: FLUCELVAX QUADRIVALENT Market Size in the UK, in USD million (2019-2032)

List of Figures

• Figure 1: FLUCELVAX QUADRIVALENT Market Size in the 6MM, USD million (2019-2032)
• Figure 2: FLUCELVAX QUADRIVALENT Market Size in the United States, USD million (2019-2032)
• Figure 3: FLUCELVAX QUADRIVALENT Market Size in Germany, USD million (2019-2032)
• Figure 4: FLUCELVAX QUADRIVALENT Market Size in France, USD million (2019-2032)
• Figure 5: FLUCELVAX QUADRIVALENT Market Size in Italy, USD million (2019-2032)
• Figure 6: FLUCELVAX QUADRIVALENT Market Size in Spain, USD million (2019-2032)
• Figure 7: FLUCELVAX QUADRIVALENT Market Size in the United Kingdom, USD million (2019-2032)

“"FLUCELVAX QUADRIVALENT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about FLUCELVAX QUADRIVALENT for seasonal influenza in the six major markets. A detailed picture of the FLUCELVAX QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the FLUCELVAX QUADRIVALENT for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FLUCELVAX QUADRIVALENT market forecast analysis for seasonal influenza in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

FLUCELVAX QUADRIVALENT (influenza vaccine) is a subunit influenza vaccine manufactured using cell-derived candidate vaccine viruses (CVV) that are propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line. These cells were adapted to grow freely in suspension in a culture medium. The virus is inactivated with B-propiolactone, disrupted by the detergent cetyltrimethylammonium bromide, and purified through several process steps. Each of the four virus strains is produced, purified separately, and then pooled to formulate the quadrivalent vaccine.

In 2019, the company announced that European Commission has issued marketing approval for its new cell-based seasonal influenza vaccine, FLUCELVAX TETRA influenza, the first cell-based quadrivalent influenza vaccine (QIVc) available in Europe and is licensed for use in people 9 years and above.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the FLUCELVAX QUADRIVALENT description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on FLUCELVAX QUADRIVALENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FLUCELVAX QUADRIVALENT research and development activities in seasonal influenza across the United States and Europe.
• The report also covers the patents information with expiry timeline around FLUCELVAX QUADRIVALENT.
• The report contains forecasted sales of FLUCELVAX QUADRIVALENT for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for FLUCELVAX QUADRIVALENT in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FLUCELVAX QUADRIVALENT Analytical Perspective by DelveInsight

In-depth FLUCELVAX QUADRIVALENT Market Assessment

This report provides a detailed market assessment of FLUCELVAX QUADRIVALENT for seasonal influenza in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

FLUCELVAX QUADRIVALENT Clinical Assessment

The report provides the clinical trials information of FLUCELVAX QUADRIVALENT for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FLUCELVAX QUADRIVALENT dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to FLUCELVAX QUADRIVALENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FLUCELVAX QUADRIVALENT in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of FLUCELVAX QUADRIVALENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FLUCELVAX QUADRIVALENT in seasonal influenza.

Key Questions:

• What is the product type, route of administration and mechanism of action of FLUCELVAX QUADRIVALENT?
• What is the clinical trial status of the study related to FLUCELVAX QUADRIVALENT in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FLUCELVAX QUADRIVALENT development?
• What are the key designations that have been granted to FLUCELVAX QUADRIVALENT for seasonal influenza?
• What is the forecasted market scenario of FLUCELVAX QUADRIVALENT for seasonal influenza?
• What are the forecasted sales of FLUCELVAX QUADRIVALENT in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to FLUCELVAX QUADRIVALENT for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. FLUCELVAX QUADRIVALENT Overview in seasonal influenza

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FLUCELVAX QUADRIVALENT Market Assessment

• 5.1. Market Outlook of FLUCELVAX QUADRIVALENT in seasonal influenza
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of FLUCELVAX QUADRIVALENT in the 6MM for seasonal influenza
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of FLUCELVAX QUADRIVALENT in the United States for seasonal influenza
  • 5.3.2. Market Size of FLUCELVAX QUADRIVALENT in Germany for seasonal influenza
  • 5.3.3. Market Size of FLUCELVAX QUADRIVALENT in France for seasonal influenza
  • 5.3.4. Market Size of FLUCELVAX QUADRIVALENT in Italy for seasonal influenza
  • 5.3.5. Market Size of FLUCELVAX QUADRIVALENT in Spain for seasonal influenza
  • 5.3.6. Market Size of FLUCELVAX QUADRIVALENT in the United Kingdom for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options